Assessment of risk perception of patients concerning adverse drug reactions

1 EC. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmaco-vigilance. Directive 2001/83/EC on the Community code relating to medicinalproducts for human us. [http://eur-lex.europa. eu/LexUriServ/LexUriServ; 2010] Search in Google Scholar

2 World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO; 2002:1-48. Search in Google Scholar

3 Vilhelmsson A, Svensson T, Meeuwisse A, Carlsten A. Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association. BMC Pharmacol Toxicol. 2012;13(1):19. Search in Google Scholar

4 Herdeiro MT, Ferreira M, Ribeiro-Vaz I, Polónia JJ, Costa Pereira A. O Sistema Português de Farmacovigilância. Acta Med Port. 2012; 25(4). Search in Google Scholar

5 Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the Pharmacovigilance System? - a Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;883-90. Search in Google Scholar

6 Matos C, Rodrigues L, Joaquim J. Attitudes and opinions of Portuguese community pharmacy professionals towards patient reporting of adverse drug reactions and the pharmacovigilance system. Drugs Ther Perspect. 2017;33(4). Search in Google Scholar

7 Matos C, Joaquim J, Pires T. Attitudes and knowledge of community pharmacy professionals regarding the spontaneous reporting of adverse drug reactions: a preliminary study in Coimbra, Portugal. Drugs Ther Perspect. 2017;33(2). Search in Google Scholar

8 Vallano A, Cereza G, Pedròs C, Agusti A, Danés I, Aguilera C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005;60(6):653-8. Search in Google Scholar

9 Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014;22(2):83-94. Search in Google Scholar

10 Aronson JK. Risk perception in drug therapy. Br J Clin Pharmacol. 2006;62(2):135-7. Search in Google Scholar

11 Alshakka MA, Ibrahim MIM, Hassali MAA. Do Health Professionals have Positive Perception Towards Consumer Reporting of Adverse Drug Reactions? J Clin Diagnostic Res. 2013;7(10):2181-5. Search in Google Scholar

12 Knapp P, Raynor DK, Berry DC. Comparison of two methods of presenting risk information to patients about the side effects of medicines. Qual Saf Heal Care. 2004;13(3):176-80. Search in Google Scholar

13 Paling J. Strategies to help patients understand risks. Br Med J. 2003;327(7417):745. Search in Google Scholar

14 Fukuda Y, Ando S, Saito M. Risk awareness, medication adherence, and driving behavior as determined by the provision of drug information to patients. Patient Educ Couns. 2020;103(8):1574-80. Search in Google Scholar

15 Britten N. Medication errors: the role of the patient. Br J Clin Pharmacol. 2009;67(6):646-50. Search in Google Scholar

16 Shrank WH, Avorn J. Educating patients about their medications: the potential and limitations of written drug information. Health Aff. 2007;26(3):731-40. Search in Google Scholar

17 Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865-9. Search in Google Scholar

18 Chinchilla K, Matos C, Hall V, van Hunsel F. Patient organizations’ barriers in pharmacovigilance and strategies to stimulate their participation. Drug Saf. 2021;44(2):181-91. Search in Google Scholar

19 van Hoof M, Chinchilla K, Härmark L, Matos C, Inácio P, van Hunsel F. Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis. Drug Saf. 2022;45(10):1083-98. Search in Google Scholar

20 Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148-56. Search in Google Scholar

21 Aishwaryalakshmi K, Sasikala B, Sreelalitha N, Vigneshwaran E, Reddy YP. Assessment of knowledge perception and attitudes on medications in general population. Editor BOARD. 2012;6. Search in Google Scholar

22 Jose J, Jimmy B, Al-Ghailani ASH, Al Majali MA. A cross sectional pilot study on assessing the knowledge, attitude and behavior of community pharmacists to adverse drug reaction related aspects in the Sultanate of Oman. Saudi Pharm J. 2014;22(2):163-9. Search in Google Scholar

23 Cullen G, Kelly E, Murray FE. Patients’ knowledge of adverse reactions to current medications. Br J Clin Pharmacol. 2006;62(2): 232-6. Search in Google Scholar

24 Jatau AI, Shitu Z, Khalid GM, Yunusa I, Awaisu A. Understanding adverse drug-related emergency department visits: Development of a conceptual model through a systematic review. Ther Adv Drug Saf. 2019;10:1-18. Search in Google Scholar

25 Bongard V, Ménard-Taché S, Bagheri H, Kabiri K, Lapeyre-Mestre M, Montastruc JL. Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. Br J Clin Pharmacol. 2002;54(4):433-6. Search in Google Scholar

26 Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med (Northfield Il). 2016;16(5):481. Search in Google Scholar

27 Montastuc JL, Bongard V, Lapeyre-Mestre M. Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists. Eur J Clin Pharmacol. 2003;59(8-9):685-8. Search in Google Scholar

28 Ferrer RA, Klein WMP. Risk perceptions and health behavior. Curr Opin Psychol. 2015;5:85-9. Search in Google Scholar

29 Matos C, van Hunsel F, Tavares Ribeiro R, do Ó D, Raposo JF. Diabetes patient’s pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation. Ther Adv Drug Saf. 2020;11:2042098620953935. Search in Google Scholar

30 Robinson F, Wilkes S, Schaefer N, Goldstein M, Rice M, Gray J, et al. Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community. Ther Adv Drug Saf. 2023;14:20420986221146416. Search in Google Scholar

31 Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf. 2010;33:1065-79. Search in Google Scholar

32 Van Hunsel F, Passier A, Van Grootheest K. Comparing patients’ and healthcare professionals’ ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67(5): 558-64. Search in Google Scholar

33 Monteiro L, Monteiro-Soares M, Matos C, Ribeiro-Vaz I, Teixeira A, Martins C. Inappropriate prescriptions in older people – translation and adaptation to Portuguese of the STOPP/START screening tool. Int J Environ Res Public Health. 2022;19(11):6896. Search in Google Scholar